ITOS ITeos Therapeutics
- 10.740
- -0.040-0.37%
ITeos Therapeutics News
ITeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity From Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical data on EOS-984
Analysts Offer Insights on Healthcare Companies: ITeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)
Top Premarket Decliners
SurgePays (SURG) shares slumped 22% Wednesday premarket after the company reported lower Q4 revenue. Latham Group (SWIM) shares dropped 18% after the company reported lower Q4 sales. Bit Origin (BTOG)
ITeos Therapeutics Is Maintained at Overweight by JP Morgan
ITeos Therapeutics Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $27
Analysts Offer Insights on Healthcare Companies: Incyte (INCY), AnaptysBio (ANAB) and ITeos Therapeutics (ITOS)
Analysts Are Bullish on These Healthcare Stocks: ITeos Therapeutics (ITOS), Viracta Therapeutics (VIRX)
HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $44 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:ITOS) with a Buy and maintains $44 price target.
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), ITeos Therapeutics (ITOS) and Rezolute (RZLT)
Wedbush Adjusts ITeos Therapeutics Price Target to $18 From $25, Maintains Outperform Rating
iTeos Therapeutics (ITOS) has an average rating of Outperform and price targets ranging from $18 to $47, according to analysts polled by Capital IQ. Price: 11.41, Change: +0.39, Percent Change: +3.54
Recap: ITeos Therapeutics Q4 Earnings
ITeos Therapeutics (NASDAQ:ITOS) reported its Q4 earnings results on Wednesday, March 6, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsITeos Therapeutics beat esti
ITeos Therapeutics GAAP EPS of -$0.85 Beats by $0.18
Express News | ITeos Therapeutics Q4 EPS $(0.85) Beats $(1.03) Estimate, Cash and Investment Position Of $632.7M Is Expected To Provide Cash Runway Through 2026
ITeos Therapeutics 4Q Loss/Shr 85c >ITOS
ITeos Therapeutics 4Q Loss/Shr 85c >ITOS
Press Release: ITeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical
ITeos to Participate in Upcoming Investor Conferences
WATERTOWN, Mass. and GOSSELIES, Belgium, March 01, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (NASDAQ:ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new
Arcus Shares Extend Gains Amid Mixed Reactions on Gilead Stake Purchase
ITeos Therapeutics Announces 2024 Strategic Priorities, Anticipated Milestones
ITeos Announces 2024 Strategic Priorities and Anticipated Milestones; Cash Balance And Investment Balance Of $644.9M As Of September 30, 2023 Expected To Provide Runway Through 2026
- TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Adenosine portfolio clinical data readouts antici
ITeos to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 03, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and developmen
Analysis
Price Target
No Data
